Meropenem Sun (Meropenem Anhydrous)

Meropenem is a broad‑spectrum carbapenem used to treat severe bacterial infections in the hospital setting.

• Complicated intra‑abdominal infection: provides rapid bactericidal activity to resolve infection.
• Complicated urinary tract infection: eliminates resistant uropathogens and clears infection.
• Nosocomial pneumonia: targets Gram‑negative and Gram‑positive pathogens causing hospital‑acquired lung infection.
• Meningitis: penetrates the cerebrospinal fluid to eradicate causative bacteria.
• Septicemia: offers systemic coverage against multidrug‑resistant organisms in bloodstream infections.

• Meropenem binds to penicillin‑binding proteins (PBPs) on bacterial cell walls, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic instability and bacterial cell death. Its high affinity for a broad range of PBPs confers activity against many Gram‑negative, Gram‑positive and anaerobic organisms, including those resistant to other β‑lactam antibiotics.

Adverse reactions may occur with meropenem therapy.

Common Side Effects

• Nausea: mild to moderate gastrointestinal discomfort.
• Diarrhea: may be watery and self‑limiting.
• Vomiting: occasional episodes during infusion.
• Headache: transient and usually resolves.
• Rash: mild skin erythema or pruritus.
• Infusion site reaction: erythema or phlebitis at the injection site.

Serious or Rare Side Effects

• Seizures: especially in patients with renal impairment or CNS disorders.
• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Clostridioides difficile‑associated diarrhea: can lead to colitis.
• Neutropenia: marked reduction in neutrophil count.
• Thrombocytopenia: low platelet levels increasing bleeding risk.
• Renal toxicity: impaired kidney function in susceptible individuals.

Clinicians should consider several safety measures before initiating meropenem.

• Renal function: adjust dose in patients with impaired kidney function.
• Allergy: avoid in individuals with known carbapenem hypersensitivity.
• Seizure risk: monitor closely in patients with a history of seizures or CNS disease.
• Pregnancy: use only when the potential benefit justifies the potential risk to the fetus.
• Drug interactions: review concomitant medications for possible interactions.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Valproic acid: meropenem can markedly reduce plasma valproate levels, increasing seizure risk.
• Other carbapenems: concurrent use may lead to additive toxicity and should be avoided.
• Cytotoxic agents: may increase nephrotoxicity when combined.

Moderate Interactions (Monitor Closely)

• Aminoglycosides: monitor renal function due to potential additive nephrotoxicity.
• Loop diuretics: watch electrolyte balance and renal clearance.
• Warfarin: may alter INR; frequent coagulation monitoring is advised.